CN Stock MarketDetailed Quotes
300255 Hebei Changshan Biochemical Pharmaceutical
- 11.34
- -0.21-1.82%
Market Closed May 17 15:00 CST
10.42BMarket Cap-7980P/E (TTM)
11.67High11.25Low202.04KlotVolume11.65Open11.55Pre Close229.39MTurnover2.21%Turnover RatioLossP/E (Static)919.06MShares17.9852wk High5.96P/B10.39BFloat Cap4.3052wk Low13.86Limit Up915.84MShs Float19.15Historical High9.24Limit Down3.64%Amplitude1.83Historical Low0.01Dividend TTM11.35Avg Price116.19KlotAsk0.04%Div YieldTTM100Lot Size83.00KlotBid
Hebei Changshan Biochemical Pharmaceutical Key Stats
All
YOY
| (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | (Q6)Jun 30, 2022 | (Q3)Mar 31, 2022 | (FY)Dec 31, 2021 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total operating revenue | -41.36%294.32M | -39.63%1.41B | -36.47%1.14B | -28.45%820.37M | -12.58%501.92M | -21.29%2.34B | -16.89%1.79B | -19.11%1.15B | -19.18%574.18M | 25.56%2.97B |
| Operating revenue | -41.36%294.32M | -39.63%1.41B | -36.47%1.14B | -28.45%820.37M | -12.58%501.92M | -21.29%2.34B | -16.89%1.79B | -19.11%1.15B | -19.18%574.18M | 25.56%2.97B |
| Other operating revenue | ---- | 37.31%13.25M | ---- | 3.76%4.68M | ---- | -64.66%9.65M | ---- | -68.35%4.51M | ---- | 179.82%27.3M |
| Total operating cost | -30.08%355.15M | -13.06%2.01B | -16.03%1.44B | -11.46%946.28M | -6.39%507.97M | -15.10%2.31B | -11.34%1.71B | -14.11%1.07B | -13.74%542.64M | 31.96%2.72B |
| Operating cost | -14.36%259.32M | -15.82%1.09B | -13.39%784.47M | -7.63%507.7M | 7.04%302.81M | 4.61%1.3B | 6.65%905.8M | -0.43%549.66M | 2.59%282.88M | 67.58%1.24B |
| Operating tax surcharges | -68.32%2.87M | -4.33%21.07M | 9.13%17.34M | 1.54%13.29M | -8.48%9.07M | -17.73%22.02M | -20.94%15.89M | -8.94%13.09M | 24.32%9.91M | 12.92%26.77M |
| Operating expense | -81.49%17.78M | -22.94%472.84M | -30.34%348.42M | -26.98%233.58M | -34.42%96.08M | -43.84%613.6M | -38.72%500.14M | -38.40%319.88M | -44.69%146.51M | 11.08%1.09B |
| Administration expense | -0.56%35.93M | 25.04%166.47M | 6.31%112.62M | 3.10%75.17M | -13.85%36.13M | 0.11%133.13M | 15.10%105.94M | 21.36%72.91M | 47.19%41.93M | 13.79%132.99M |
| Financial expense | -10.31%22.81M | -1.38%92.94M | 6.88%76.24M | 2.26%46.47M | 0.65%25.43M | 29.91%94.25M | 43.25%71.33M | 52.00%45.45M | 129.53%25.26M | 9.27%72.54M |
| -Interest expense (Financial expense) | -18.20%18.9M | 3.62%96.41M | 11.74%77.39M | 11.64%48.71M | 12.39%23.1M | 49.36%93.04M | 62.22%69.25M | 61.35%43.63M | 67.46%20.56M | 11.63%62.29M |
| -Interest Income (Financial expense) | 37.53%-385.86K | 7.65%-1.84M | -13.26%-1.42M | -48.21%-1.15M | -140.92%-617.66K | -54.16%-1.99M | -34.61%-1.25M | -5.56%-778.84K | 37.41%-256.38K | 21.12%-1.29M |
| Research and development | -57.26%16.44M | 9.52%158.82M | -12.88%100.56M | 3.42%70.07M | 6.40%38.45M | -3.73%145.01M | 8.48%115.42M | -1.18%67.75M | -11.85%36.14M | 18.10%150.63M |
| Credit Impairment Loss | -153.06%-848.41K | -175.27%-25.92M | 145.06%422.67K | 498.73%1.24M | 213.53%1.6M | -231.20%-9.42M | -25.11%-938.1K | 70.88%-310.24K | -3.52%-1.41M | 51.84%-2.84M |
| Asset Impairment Loss | ---- | -5,380.77%-633.32M | ---121.35M | ---51.32M | ---- | ---11.56M | ---- | ---- | ---- | ---- |
| Other net revenue | -88.90%1.31M | -6,682.34%-631.55M | -1,631.00%-106.24M | -1,289.87%-37.21M | 575.77%11.79M | -187.74%-9.31M | -12.06%6.94M | -29.99%3.13M | -4.10%1.75M | 156.52%10.61M |
| Invest income | ---- | --7.02K | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Asset deal income | ---- | 152.67%7K | ---- | ---- | ---- | ---13.29K | ---13.29K | ---17.16K | ---17.16K | ---- |
| Other revenue | -78.84%2.16M | 137.08%27.68M | 86.16%14.69M | 272.72%12.87M | 221.52%10.2M | -13.24%11.67M | -8.69%7.89M | -37.55%3.45M | -0.30%3.17M | 34.00%13.46M |
| Operating profit | -1,134.67%-59.52M | -6,095.95%-1.23B | -571.28%-406.28M | -301.66%-163.11M | -82.72%5.75M | -92.19%20.45M | -62.93%86.21M | -54.46%80.88M | -60.00%33.28M | -15.26%262M |
| Add:Non operating Income | 759.62%80.02K | -13.92%184.17K | 951.98%131.7K | 601.72%47.44K | 727.59%9.31K | 41.10%213.95K | -74.23%12.52K | -82.54%6.76K | -470.08%-1.48K | -35.41%151.64K |
| Less:Non operating expense | 289.53%69.37K | 117.79%5.55M | -68.91%781.98K | -57.78%276.47K | -64.38%17.81K | 46.46%2.55M | 142.92%2.52M | 1,915.02%654.89K | -54.46%50K | -77.89%1.74M |
| Total profit | -1,136.02%-59.51M | -6,898.82%-1.23B | -586.15%-406.93M | -303.57%-163.34M | -82.72%5.74M | -93.04%18.12M | -63.85%83.7M | -54.83%80.24M | -60.01%33.23M | -13.65%260.41M |
| Less:Income tax cost | -51.88%2.5M | 106.77%16.46M | -153.36%-11.99M | -111.50%-2.15M | 18.38%5.19M | -72.69%7.96M | -15.31%22.47M | -13.96%18.67M | -71.45%4.38M | -42.19%29.15M |
| Net profit | SL-62.01M | SL-1.25B | SL-394.94M | SL-161.19M | -98.06%558.68K | -95.61%10.16M | -70.13%61.24M | -60.51%61.56M | -57.42%28.85M | -7.92%231.26M |
| Net profit from continuing operation | -11,198.61%-62.01M | -12,389.70%-1.25B | -744.91%-394.94M | -361.83%-161.19M | -98.06%558.68K | -95.61%10.16M | -70.13%61.24M | -60.51%61.56M | -57.42%28.85M | -7.92%231.26M |
| Less:Minority Profit | 91.44%-340.82K | -7.96%-7.94M | -9.25%-6.61M | -66.25%-5.31M | -398.18%-3.98M | -218.18%-7.36M | -197.52%-6.05M | -205.62%-3.2M | 0.21%-799.47K | -35.87%-2.31M |
| Net profit of parent company owners | -1,457.82%-61.67M | -7,181.47%-1.24B | -677.10%-388.33M | -340.70%-155.88M | -84.68%4.54M | -92.50%17.51M | -67.51%67.29M | -58.74%64.76M | -56.75%29.65M | -7.62%233.57M |
| Earning per share | ||||||||||
| Basic earning per share | -1,469.39%-0.0671 | -6,850.00%-1.35 | -700.00%-0.42 | -342.86%-0.17 | -84.54%0.0049 | -92.00%0.02 | -68.40%0.07 | -58.82%0.07 | -54.71%0.0317 | -7.41%0.25 |
| Diluted earning per share | -1,469.39%-0.0671 | -6,850.00%-1.35 | -700.00%-0.42 | -342.86%-0.17 | -84.54%0.0049 | -92.00%0.02 | -68.40%0.07 | -58.82%0.07 | -54.71%0.0317 | -7.41%0.25 |
| Other composite income | 93.62%-43.4K | 63.68%-1.58M | 79.86%-928.53K | 75.63%-874.46K | 59.14%-680.35K | 64.78%-4.36M | 49.01%-4.61M | 29.24%-3.59M | -1,368.99%-1.66M | -203.27%-12.37M |
| Other composite income of parent company owners | 93.62%-43.4K | 63.68%-1.58M | 79.86%-928.53K | 75.63%-874.46K | 59.14%-680.35K | 64.78%-4.36M | 49.01%-4.61M | 29.24%-3.59M | -1,368.99%-1.66M | -203.27%-12.37M |
| Total composite income | -50,897.29%-62.05M | -21,647.93%-1.25B | -799.07%-395.87M | -379.54%-162.07M | -100.45%-121.67K | -97.35%5.8M | -71.11%56.63M | -61.57%57.98M | -59.81%27.19M | -16.81%218.89M |
| Total composite income of parent company owners | -1,698.20%-61.71M | -9,538.15%-1.24B | -721.04%-389.26M | -356.25%-156.75M | -86.20%3.86M | -94.05%13.16M | -68.35%62.68M | -59.73%61.17M | -59.11%27.99M | -16.47%221.2M |
| Total composite income of minority owners | 91.44%-340.82K | -7.96%-7.94M | -9.25%-6.61M | -66.25%-5.31M | -398.18%-3.98M | -218.18%-7.36M | -197.52%-6.05M | -205.62%-3.2M | 0.21%-799.47K | -35.87%-2.31M |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion |
| Auditor | -- | Zhongxi Certified Public Accountants (Special General Partnership) | -- | -- | -- | Zhongxi Certified Public Accountants (Special General Partnership) | -- | -- | -- | Zhongxi Certified Public Accountants (Special General Partnership) |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
Analysis
Price Target
No Data
Heat List
CN
Overall
Symbol
Latest Price
%Chg